Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | RPLP1 | P05386 | 1/20 | 0.31 |
| ▸ | RPLP0 | P05388 | 1/20 | 0.31 |
| ▸ | RPS17 | P08708 | 1/20 | 0.31 |
| ▸ | RPSA | P08865 | 1/20 | 0.31 |
| ▸ | RPS2 | P15880 | 1/20 | 0.31 |
| ▸ | RPL35A | P18077 | 1/20 | 0.31 |
| ▸ | RPL7 | P18124 | 1/20 | 0.31 |
| ▸ | RPL17 | P18621 | 1/20 | 0.31 |
| ▸ | RPS4Y1 | P22090 | 1/20 | 0.31 |
| ▸ | RPS3 | P23396 | 1/20 | 0.31 |
| ▸ | RPS12 | P25398 | 1/20 | 0.31 |
| ▸ | RPL13 | P26373 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29942174 | 1.00 | RXFP1 (0.35) | RXFP1PIK3CBMAPTLMNACYP3A4 | |
| SCHEMBL30122603 | 0.96 | RXFP1 (0.33) | RXFP1PIK3CBMAPTLMNACYP3A4 | |
| SCHEMBL19117686 | 0.78 | CYP2A6 (0.41) | PIK3CBMAPTRPLP1RPLP0RPS17 | |
| SCHEMBL23346951 | 0.76 | PIK3CB (0.42) | PIK3CBMAPT | |
| SCHEMBL20987529 | 0.76 | PIK3CB (0.38) | PIK3CBMAPTSCN9ALPO | |
| SCHEMBL22863238 | 0.76 | PIK3CB (0.34) | PIK3CBMAPTRPLP1RPLP0RPS17 | |
| SCHEMBL29777078 | 0.76 | PIK3CB (0.34) | PIK3CBMAPTRPLP1RPLP0RPS17 | |
| SCHEMBL18534997 | 0.76 | PIK3CB (0.34) | PIK3CBMAPTSCN9ALPO | |
| SCHEMBL18726700 | 0.76 | LMNA (0.32) | MAPTLMNACYP3A4APEX1MAPK1 | |
| SCHEMBL2228004 | 0.76 | DGAT1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4103559-B1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12473304-B2 | Heterocyclic PAD4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20230357241-A1 | 1H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS AND APPLICATION THEREOF | JUMBO DRUG BANK CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357241-A1 | 1H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS AND APPLICATION THEREOF | JUMBO DRUG BANK CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4219459-A1 | 1H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS AND APPLICATION THEREOF | Jumbo Drug Bank Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| EP-1904504-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | Methylgene, Inc. (CA) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007054831-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007054831-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2007-05-18 | — | — | WO | disclosed |
| EP-1781664-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | Methylgene, Inc. (CA) | 2007-05-09 | — | — | EP | disclosed |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. (CA) | 2006-04-06 | — | — | US | disclosed |
| WO-2006010264-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473304-B2 | Heterocyclic PAD4 inhibitors | PADI6, PADI4, PADI1 | RXFP1 707/4885PIK3CB 2617/4885MAPT 4383/4885 |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | RXFP1 1056/4885PIK3CB 733/4885MAPT 2430/4885 |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, FLT1 | RXFP1 1056/4885PIK3CB 733/4885MAPT 2430/4885 |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | HGF, MET, FLT1 | RXFP1 1080/4885PIK3CB 679/4885MAPT 2320/4885 |
| US-20230357241-A1 | 1H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS AND APPLICATION THEREOF | PAH, NPPA, JAK2 | RXFP1 1517/4885PIK3CB 1498/4885MAPT 2150/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | RXFP1 4760/4885PIK3CB 3361/4885MAPT 2934/4885 |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI2, PADI6 | RXFP1 4486/4885PIK3CB 893/4885MAPT 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.